

West Virginia Medicaid Drug Utilization Review Board Minutes

February 19,2020

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance;

Members:

K.C. Lovin, PA-C, Chair
Christopher Terpening, PharmD, PhD, Vice Chair
C.K. Babcock, PharmD
Chris Booth, PharmD
Scott Brown, RPh
Myra Chiang, MD
Kate Forman, PharmD
Phillip Galapon, MD
David Gloss, MD
Michael Lonsinger, PharmD
Ernest Miller, DO
Mary Nemeth-Pyles, MSN, RN, CS
John Vanin, MD

Members Absent:

Michael Ballow, PharmD
Lester Labus, MD

DHHR/BMS Staff:

Brian Thompson, MS, PharmD, Director of Pharmacy Services
Lori Moles, RPh, Staff Pharmacist
Bill Hopkins, Pharmacy operations Manager
Doug Sorvig, Administrative Assistant

Contract Staff:

Angie Wowczuk, PharmD, Rational Drug Therapy Program (RDTP)
Kim Broedel-Zaugg, RPh, PhD, Marshall University
Jon Willis, Marshall University
Eric Sears, RPh, DXC
Brent Breeding, RPh, Change Healthcare, phone in
Jacqueline Hedlund, MD, Change Healthcare, phone in

I. INTRODUCTIONS

- a. K.C. Lovin, Chair, welcomed everyone to the Board meeting at 4:04pm EDT. The DUR Board and attendees introduced themselves.

II. APPROVAL OF MINUTES FROM November 20, 2019 DUR BOARD MEETING

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

III. OLD BUSINESS

none

IV. NEW BUSINESS

a. Speakers

i. none

b. Updates from January 22, 2020 P & T Committee Meeting

i. None, meeting was cancelled

c. PDL Prior Authorization Criteria. Attachment A

i. **Xhance:** approved as amended

ii. **Dupixent:** approved as amended

iii. **PCSK-9 Inhibitors:** approved as presented

iv. **Exondys 51:** approved as presented

v. **Vyondys 53:** approved as presented

vi. **Lipotropics, Other (non-statins)-Vascepa:** approved as amended

vii. **PDL Adjustments (introduced during the meeting):**

a. Baraclude Solution: approved as presented

b. Truvada: Approved as presented

c. Toujeo and Toujeo Max Solostar: Approved as presented

V. REPORTS

a. DXC Quarterly Report: Mr. Sears presented an overview of the 2019 Third Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.

b. Rational Drug Therapy Program: Dr. Wowczuk presented a review of the prior authorization program for the Third Quarter of 2019. Attachment C

c. Marshall University Coalition: Dr. Broedel-Zaugg reported on the progress of retro DUR, the lock in program, number of letters sent/returned, and requested board members to rank public health initiatives. Attachment D

VI. OTHER BUSINESS

a. None

VII. NEXT MEETING AND ADJOURNMENT

VIII. a. A motion to adjourn the meeting was made, seconded, and approved.

b. The meeting concluded at 5:15pm EDT.

c. The next meeting will be May 27, 2020 from 4:00pm to 6:00pm and located at WVDHHR.